Literature DB >> 10390402

The cost of asthma in the emergency department and hospital.

R Stanford1, T McLaughlin, L J Okamoto.   

Abstract

Treatment of asthma in the emergency department (ED) or hospital accounts for a significant portion of total treatment costs; however, little is known about the specific resources consumed. The purpose of this study was to estimate the type and amount of resources consumed for an asthma event requiring ED visit and/or hospitalization. Between October 1, 1996 and September 30, 1997, occurrences of asthma as a primary diagnosis were identified at 27 hospitals' emergency departments within Premier's Perspective Comparative Database. Patients visiting the ED could either be treated and released or admitted to the hospital. A total of 3,223 patients (age >/= 18 yr) were identified, with 1,074 (33.3%) requiring hospitalization. For the 2,149 patients who visited the ED only, the average visit cost was $234.48. For hospitalized patients, the average length of stay was 3.8 d, and the cost was $3,102.53. Nursing care was the source of the majority of hospital costs for asthma (43.6%), respiratory therapy (13.6%), and medications (10.4%). For adult asthma patients requiring hospitalization, the total cost is high and resources consumed are unavoidable. Thus, a continuum of care aimed at appropriate asthma management, especially in the elderly, could result in substantial cost savings over those aimed at reducing inpatient utilization of care.

Entities:  

Mesh:

Year:  1999        PMID: 10390402     DOI: 10.1164/ajrccm.160.1.9811040

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  24 in total

1.  Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients.

Authors:  Hakon Hakonarson; Unnur S Bjornsdottir; Eva Halapi; Jonathan Bradfield; Florian Zink; Magali Mouy; Hildur Helgadottir; Asta S Gudmundsdottir; Hjalti Andrason; Asdis E Adalsteinsdottir; Kristleifur Kristjansson; Illugi Birkisson; Thor Arnason; Margret Andresdottir; David Gislason; Thorarinn Gislason; Jeffrey R Gulcher; Kari Stefansson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

2.  Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic medicaid population.

Authors:  Seung Jin Bae; A David Paltiel; Anne L Fuhlbrigge; Scott T Weiss; Karen M Kuntz
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

3.  Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.

Authors:  R Menendez; R H Stanford; L Edwards; C Kalberg; K Rickard
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Ozone-related asthma emergency department visits in the US in a warming climate.

Authors:  Nicholas Nassikas; Keith Spangler; Neal Fann; Christopher G Nolte; Patrick Dolwick; Tanya L Spero; Perry Sheffield; Gregory A Wellenius
Journal:  Environ Res       Date:  2020-01-31       Impact factor: 6.498

5.  Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.

Authors:  Ketan Sheth; Rohit Borker; Amanda Emmett; Kathleen Rickard; Paul Dorinsky
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Factors associated with completion of a behavioral intervention for caregivers of urban children with asthma.

Authors:  Arlene M Butz; Jill S Halterman; Melissa Bellin; Joan Kub; Kevin D Frick; Cassia Lewis-Land; Jennifer Walker; Michele Donithan; Mona Tsoukleris; Mary Elizabeth Bollinger
Journal:  J Asthma       Date:  2012-09-19       Impact factor: 2.515

7.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module.

Authors:  Anna R Wolfson; Li Zhou; Yu Li; Neelam A Phadke; Ohn A Chow; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2018-08-31

8.  Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.

Authors:  Paul Howard; Christopher Knight; Annabel Boler; Christine Baker
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.

Authors:  Ann C Wu; A David Paltiel; Karen M Kuntz; Scott T Weiss; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol       Date:  2007-09-29       Impact factor: 10.793

Review 10.  Economic burden of asthma: a systematic review.

Authors:  Katayoun Bahadori; Mary M Doyle-Waters; Carlo Marra; Larry Lynd; Kadria Alasaly; John Swiston; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2009-05-19       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.